Now showing items 1-8 of 8

    • Compliance with results reporting at ClinicalTrials.gov. 

      Anderson, ML; Califf, Robert M; Chiswell, K; Peterson, Eric David; Tasneem, Asba; Topping, J (N Engl J Med, 2015-03-12)
      BACKGROUND: The Food and Drug Administration Amendments Act (FDAAA) mandates timely reporting of results of applicable clinical trials to ClinicalTrials.gov. We characterized the proportion of applicable clinical trials ...
    • Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. 

      Califf, Robert M; Lin, L; Schulman, Kevin Alan; Seils, DM; Tzeng, JP; Weinfurt, Kevin Phillip (PLoS One, 2008-05-07)
      BACKGROUND: Disclosure of authors' financial interests has been proposed as a strategy for protecting the integrity of the biomedical literature. We examined whether authors' financial interests were disclosed consistently ...
    • Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials. 

      Khan, MS; Krasuski, Richard Andrew; Raza, S; Riaz, H; Riaz, IB (Am J Cardiol, 2015-12-15)
      Previous authors have suggested a higher likelihood for industry-sponsored (IS) studies to have positive outcomes than non-IS studies, though the influence of publication bias was believed to be a likely confounder. We attempted ...
    • Issues in regulatory guidelines for data monitoring committees. 

      Califf, Robert M; DeMets, David Leon; Dixon, Dennis; Ellenberg, S; Fleming, T; Held, P; Julian, D; ... (19 authors) (Clin Trials, 2004)
      As clinical trials have emerged as the major research method for evaluating new interventions, the process for monitoring intervention safety and benefit has also evolved. The Data Monitoring Committee (DMC) has become the ...
    • Race disparity in grants: check the citations. 

      Erickson, Harold Paul (Science (New York, N.Y.), 2011-11)
    • Returns to R&D on new drug introductions in the 1980s. 

      Grabowski, Henry G; Vernon, John M (J Health Econ, 1994-12)
      This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ...
    • The distribution of sales revenues from pharmaceutical innovation. 

      Grabowski, Henry G; Vernon, John M (Pharmacoeconomics, 2000)
      OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ...
    • The price of innovation: new estimates of drug development costs. 

      DiMasi, Joseph A; Grabowski, Henry G; Hansen, Ronald W (J Health Econ, 2003-03)
      The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...